Close Menu

NEW YORK – Japan's Ministry of Health, Labor and Welfare has approved Myriad Genetics' BRACAnalysis Diagnostic System for identifying breast cancer patients with germline BRCA1 and BRCA2 mutations. 

The approval allows physicians in Japan to order BRACAnalysis for women with breast cancer who meet certain criteria established by the Japanese Organization of Hereditary Breast and Ovarian Cancer (JBHBOC). Patients who test positive for a deleterious BRCA1/2 mutation may then be recommended for prophylactic surgeries or targeted treatments. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.